Exxel Pharma Inc. (EXXL)

Exxel Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Revenue	0.23	0.23	0.1
Revenue Growth (YoY)	-	125.00%	-
Gross Profit	0.23	0.23	0.1
Selling, General & Admin	-	0.51	0.42
Research & Development	-	0.09	0.1
Operating Expenses	-	0.6	0.52
Operating Income	-0.88	-0.38	-0.42
Interest Expense (Income)	0.22	0.03	-
Other Expense (Income)	0.18	0	0.01
Pretax Income	-1.27	-0.41	-0.43
Net Income	-1.27	-0.41	-0.43
Free Cash Flow	-0.77	-0.36	-0.4
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-389.29%	-167.00%	-420.62%
Profit Margin	-565.54%	-181.85%	-430.10%
Free Cash Flow Margin	-341.73%	-160.23%	-399.76%
EBITDA	-0.84	-0.35	-0.43
EBITDA Margin	-372.13%	-154.19%	-430.10%
Depreciation & Amortization	0.22	0.03	-
EBIT	-1.05	-0.38	-0.43
EBIT Margin	-468.84%	-168.04%	-430.10%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).